@article{5c6ac73ad5344a40a4d88f22b2b13ac9,
title = "The binding property of a monoclonal antibody against the extracellular domains of aquaporin-4 directs aquaporin-4 toward endocytosis",
abstract = "Neuromyelitis optica (NMO), an autoimmune disease of the central nervous system, is characterized by an autoantibody called NMO-IgG that recognizes the extracellular domains (ECDs) of aquaporin-4 (AQP4). In this study, monoclonal antibodies (mAbs) against the ECDs of mouse AQP4 were established by a baculovirus display method. Two types of mAb were obtained: one (E5415A) recognized both M1 and M23 isoforms, and the other (E5415B) almost exclusively recognized the square-array-formable M23 isoform. While E5415A enhanced endocytosis of both M1 and M23, followed by degradation in cells expressing AQP4, including astrocytes, E5415B did so to a much lesser degree, as determined by live imaging using fluorescence-labeled antibodies and by Western blotting of lysate of cells treated with these mAbs. E5415A promoted cluster formation of AQP4 on the cell surface prior to endocytosis as determined by immunofluorescent microscopic observation of bound mAbs to astrocytes as well as by Blue native PAGE analysis of AQP4 in the cells treated with the mAbs. These observations clearly indicate that an anti-AQP4-ECDs antibody possessing an ability to form a large cluster of AQP4 by cross-linking two or more tetramers outside the AQP4 arrays enhances endocytosis and the subsequent lysosomal degradation of AQP4.",
keywords = "Aquaporin-4, Astrocyte, Autoimmune disease, Endocytosis, Monoclonal antibody, Neuromyelitis optica",
author = "Ping Huang and Yoshiki Takai and Osamu Kusano-Arai and Julia Ramadhanti and Hiroko Iwanari and Takayuki Miyauchi and Toshiko Sakihama and Han, {Jing Yan} and Masashi Aoki and Takao Hamakubo and Kazuo Fujihara and Masato Yasui and Yoichiro Abe",
note = "Funding Information: This work was supported by grants from Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C) ( 22590940 ) (YA); Keio Gijuku Academic Development Funds (YA); Grant-in-Aid for Scientific Research (B) ( 21390061 ) (MY); the Japan New Energy and Industrial Technology Development Organization ( NEDO, P08005 ) (MY); Keio University Special Grant-in-Aid for Innovative Collaborative Research Projects (MY); Translational Research Network Program from Japan Agency for Medical Research and Development ( A151TR ) (MY); FIRST program of Japan Society for the Promotion of Science (TH); Grants-in Aid for Scientific Research from the Ministry of Education, Science and Technology of Japan ( 25220205 ) (TH); the NFAT project of the Japan New Energy and Industrial Technology Development Organization ( NEDO, P06009 ) (TH); the Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology of Japan ( 22229008 ) (KF); Grants-in-Aid for Scientific Research (Research of Neuroimmunological Diseases) from the Ministry of Health, Welfare and Labor of Japan ( 201324020A ) (KF). Publisher Copyright: {\textcopyright} 2016 The Authors.",
year = "2016",
month = sep,
day = "1",
doi = "10.1016/j.bbrep.2016.05.017",
language = "English",
volume = "7",
pages = "77--83",
journal = "Biochemistry and Biophysics Reports",
issn = "2405-5808",
publisher = "Elsevier BV",
}